Angiotech Pharmaceuticals (Vancouver, British Columbia) reported that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act (HSR) has expired pertaining to the proposed grant of an exclusive license to Boston Scientific (Natick, Massachusetts) with respect to the use of paclitaxel and other agents on medical devices in the coronary vascular field of use.